Approximately 15–20% of all instances of BrCa are human epidermal growth factor receptor 2 positive (HER2+) [3], which exhibits aggressive biological and clinical behavior and is linked to disease recurrence, metastasis, and unfavorable prognoses [4, 5]. The gene discussed is ERBB2; the disease is invasive breast carcinoma.